{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:06:04Z","timestamp":1784779564517,"version":"3.55.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Oral ibrutinib and venetoclax (I+V) demonstrate activity as monotherapy in marginal zone lymphoma (MZL), with low complete response (CR) rates. I+V has shown good clinical activity with acceptable tolerability in other malignancies. We conducted a single-site, phase 2 trial of daily I+V in patients with MZL. Ibrutinib commenced at 560 mg daily; after 4 weeks, venetoclax commenced with weekly dose escalation to 400 mg daily. Combination therapy continued until disease progression or toxicity. The primary end point was week 16 CR. Minimal residual disease (MRD) was assessed by flow cytometry in bone marrow and peripheral blood. Patients achieving eradication of MRD could enter elective treatment interruption (ETI). Fifteen patients with MZL were treated; 14 are included in efficacy analysis, and 15 were evaluable for safety. Overall response was 79% (95% confidence interval [CI], 49-95) by F-fluorodeoxyglucose\u2013positron-emission tomography (CR rate, 43%; 95% CI, 18-71). By computed tomography, 16-week CR rate was 29% (95% CI, 8-58). Best response within 56 weeks was 57% CR (95% CI, 37-80), which is higher than historic ibrutinib-monotherapy control (3% CR; P&amp;lt; .001). MRD clearance at week 56 was 40%. Six MRD-negative CR patients entered ETI, with 4 remaining disease-free at a median of 4 years. With a median follow-up of 5.5 years for the whole cohort, the 5-year progression-free survival estimate was 56% (95% CI, 27-78). I+V is safe and effective for MZL, with higher CR than with ibrutinib. Durable, ongoing CR was observed in MRD-negative patients. This trial was registered at www.clinicaltrials.gov as #NCT02471391.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016646","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:55:48Z","timestamp":1765486548000},"page":"1733-1742","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-4675","authenticated-orcid":false,"given":"Sasanka M.","family":"Handunnetti","sequence":"first","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"},{"name":"3Department of Clinical Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-5373","authenticated-orcid":false,"given":"Amit","family":"Khot","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-0022","authenticated-orcid":false,"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia"},{"name":"5Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-681X","authenticated-orcid":false,"given":"Kate","family":"Burbury","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7329-6605","authenticated-orcid":false,"given":"David","family":"Ritchie","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"},{"name":"6ACRF Translational Research Laboratory, The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-0824","authenticated-orcid":false,"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"},{"name":"7Department of Medicine, The University of Melbourne, St Vincent\u2019s Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"Burke","sequence":"additional","affiliation":[{"name":"8Clinical Trials Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-8934","authenticated-orcid":false,"given":"Rachel","family":"Koldej","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"},{"name":"6ACRF Translational Research Laboratory, The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-9596","authenticated-orcid":false,"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[{"name":"4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia"},{"name":"9Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Di Iulio","sequence":"additional","affiliation":[{"name":"9Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Westerman","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-1343","authenticated-orcid":false,"given":"Stephen","family":"Lade","sequence":"additional","affiliation":[{"name":"5Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"},{"name":"10Blood Cells and Blood Cancers, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia"},{"name":"11Clinical Haematology Department, Alfred Hospital, Melbourne, VIC, Australia"},{"name":"12School of Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-0215","authenticated-orcid":false,"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia"},{"name":"10Blood Cells and Blood Cancers, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026030915413386500_bib1","first-page":"399","volume-title":"WHO Classification of Tumours Editorial Board, eds. Vol 11","year":"2024","edition":"5th ed."},{"issue":"17","key":"2026030915413386500_bib2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026030915413386500_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"2026030915413386500_bib4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group protocol E4402","volume":"173","author":"Williams","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2026030915413386500_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026030915413386500_bib6","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma","volume":"6","author":"Alderuccio","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2026030915413386500_bib7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026030915413386500_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hon.2334","article-title":"The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma","volume":"35","author":"Laribi","year":"2017","journal-title":"Hematol Oncol"},{"issue":"3","key":"2026030915413386500_bib9","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"issue":"22","key":"2026030915413386500_bib10","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"17","key":"2026030915413386500_bib11","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"35","key":"2026030915413386500_bib12","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026030915413386500_bib13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026030915413386500_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 2","key":"2026030915413386500_bib15","doi-asserted-by":"crossref","first-page":"e70079","DOI":"10.1002\/hon.70079","article-title":"Marginal zone lymphoma: treatment update with a focus on systemic approaches","volume":"43","author":"Smith","year":"2025","journal-title":"Hematol Oncol"},{"issue":"9","key":"2026030915413386500_bib16","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J Exp Med"},{"key":"2026030915413386500_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcancer.2016.07.003","article-title":"MALT lymphoma: a paradigm of NF-kB dysregulation","volume":"39","author":"Du","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"2026030915413386500_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2026030915413386500_bib19","first-page":"864","article-title":"Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia","volume":"11","author":"Lai","year":"1998","journal-title":"Mod Pathol"},{"issue":"29","key":"2026030915413386500_bib20","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2026030915413386500_bib21","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026030915413386500_bib22","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026030915413386500_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"2026030915413386500_bib24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/cancers13051002","article-title":"Apoptotic blocks in primary non-Hodgkin B cell lymphomas identified by BH3 profiling","volume":"13","author":"Rys","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026030915413386500_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2023023388","article-title":"Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions","volume":"144","author":"Handunnetti","year":"2024","journal-title":"Blood"},{"issue":"suppl 2","key":"2026030915413386500_bib26","first-page":"200","article-title":"Ibrutinib combined with venetoclax in patients with relapsed\/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 SYMPATICO study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"22","key":"2026030915413386500_bib27","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026030915413386500_bib28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16","key":"2026030915413386500_bib29","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2026030915413386500_bib30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2026030915413386500_bib31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"34","key":"2026030915413386500_bib32","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026030915413386500_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026030915413386500_bib34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026030915413386500_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026030915413386500_bib36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bjh.17703","article-title":"Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma","volume":"194","author":"Lyu","year":"2021","journal-title":"Br J Haematol"},{"key":"2026030915413386500_bib37","volume-title":"Common terminology criteria for adverse events (CTCAE), version 4.0","year":"2010"},{"issue":"12","key":"2026030915413386500_bib38","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2026030915413386500_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.27704","article-title":"Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients","volume":"119","author":"Heilgeist","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"2026030915413386500_bib40","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1733\/2506421\/blooda_adv-2025-016646-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1733\/2506421\/blooda_adv-2025-016646-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:41:40Z","timestamp":1773085300000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1733\/557278\/Venetoclax-and-ibrutinib-induces-durable-clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016646","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,27]]}}}